Anatabine is not treating the disease in most cases, but potentially the symptoms. Unless the disease is inflammation...
Wrong. For a fledgeling biotech, it is usually dilution at the shareholders expense
More than likely, pps will go viral well before FDA approval. It would be the procession of successful trials that would spike the share price.
That is far from reality. For example, they could go bankrupt far sooner then, or much later then, a hypothetical FDA decison/rejection
If they are human, they are fallible. So far, this is research, not fact. Research is mostly trial and error, that is expected. No one said anything about fraud. That is your own paranoid reaction, not mine.
Is that the case? Feel free to furnish evidence to support this bold statement.
You obviously are not familiar with biotech timelines. Don't hold your breath. Time frames always slip in this biz...it is baked into the cake, or should be anyway.
More naïveté. There is no escrow/earmark for this, I don't believe. But no worries, if they run low on capital, they usually can dilute time and time again to stay solvent. However, maybe you should worry...there is always a good chance we will lose 90% of our investment.
So...If anatabine fails, these scientists are incompetent? That is a pretty superficial way to look at it. Sometimes things, ideas, or theories don't work out, no matter how bright individuals are. Is that their fault, or the molecule's? You decide...